Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and VXLD for Relapsed/Refractory Adult ALL
NCT01769209Phase 2Completed
- Sponsor
- Stanford University
- Start
- Mar 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by Stanford University. Started Mar 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01769209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769209.